Savings from biosimilar medicines alone increased to $12.4 billion in 2023 and $36 billion since the first biosimilar entry in 2015, according to AAM's latest report.
Generic Lucemyra is indicated for symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment.
Brimonidine Tartrate Ophthalmic Solution, 0.1%, is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.